Advancing orphan drug development for rare diseases.
作者信息
Ko Jung Min
机构信息
Division of Clinical Genetics, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
Rare Disease Center, Seoul National University Hospital, Seoul, Korea.
出版信息
Clin Exp Pediatr. 2024 Jul;67(7):356-357. doi: 10.3345/cep.2023.01109. Epub 2023 Nov 17.
Abstract
摘要
相似文献
1
Advancing orphan drug development for rare diseases.
Clin Exp Pediatr. 2024 Jul;67(7):356-357. doi: 10.3345/cep.2023.01109. Epub 2023 Nov 17.
2
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Orphanet J Rare Dis. 2017 Jan 5;12(1):1. doi: 10.1186/s13023-016-0551-7.
3
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
Orphanet J Rare Dis. 2021 Jun 9;16(1):265. doi: 10.1186/s13023-021-01901-6.
4
A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
Orphanet J Rare Dis. 2023 Jun 23;18(1):163. doi: 10.1186/s13023-023-02790-7.
5
The impact of orphan drug policies in treating rare diseases.
Health Info Libr J. 2019 Jun;36(2):179-184. doi: 10.1111/hir.12256. Epub 2019 Apr 1.
6
Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
Therapie. 2020 Apr;75(2):133-139. doi: 10.1016/j.therap.2020.02.003. Epub 2020 Feb 13.
7
Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
Orphanet J Rare Dis. 2013 Nov 15;8:179. doi: 10.1186/1750-1172-8-179.
8
Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Pharmaceut Med. 2020 Feb;34(1):19-29. doi: 10.1007/s40290-019-00317-9.
9
Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
Orphanet J Rare Dis. 2016 May 12;11(1):60. doi: 10.1186/s13023-016-0443-x.
10
Pediatric Orphan Drug Indications: 2010-2018.
Pediatrics. 2020 Apr;145(4). doi: 10.1542/peds.2019-3128. Epub 2020 Mar 3.
引用本文的文献
1
Visual Research of Global Orphan Drug from a Bibliometric Perspective.
Drug Des Devel Ther. 2025 May 20;19:4201-4220. doi: 10.2147/DDDT.S506112. eCollection 2025.
本文引用的文献
1
Development of orphan drugs for rare diseases.
Clin Exp Pediatr. 2024 Jul;67(7):315-327. doi: 10.3345/cep.2023.00535. Epub 2023 Jun 28.
2
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
Orphanet J Rare Dis. 2021 Jun 9;16(1):265. doi: 10.1186/s13023-021-01901-6.
3
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
Value Health. 2020 Dec;23(12):1580-1591. doi: 10.1016/j.jval.2020.06.020. Epub 2020 Oct 31.
4
Pediatric Orphan Drug Indications: 2010-2018.
Pediatrics. 2020 Apr;145(4). doi: 10.1542/peds.2019-3128. Epub 2020 Mar 3.
5
The burden of rare diseases.
Am J Med Genet A. 2019 Jun;179(6):885-892. doi: 10.1002/ajmg.a.61124. Epub 2019 Mar 18.
6
Collaboration for rare disease drug discovery research.
F1000Res. 2014 Oct 31;3:261. doi: 10.12688/f1000research.5564.1. eCollection 2014.
7
Advocacy groups and their role in rare diseases research.
Adv Exp Med Biol. 2010;686:515-25. doi: 10.1007/978-90-481-9485-8_28.
Zotero 插件